FDA Class II

Veridian Glucose Patch (VGP-200)

510(k) Number: K231156

Wearable continuous glucose monitoring patch for diabetes management in adults with Type 1 and Type 2 diabetes.

Canonical URL: /regulatory/devices/veridian-glucose-patch-k231156.html
510(k) Number: K231156
Product Code: NBW
Regulation: 21 CFR 862.1355
UDI-DI: 00842684702345
Decision Date: 2023-09-22
Clinical Trial: VRD-CT-2024-001

510(k) Clearance Summary

FieldValue
Device NameVeridian Glucose Patch, Model VGP-200
510(k) NumberK231156
Decision DateSeptember 22, 2023
Product CodeNBW — Glucose monitor, invasive, continuous
Regulation Number21 CFR 862.1355
Predicate DeviceGlucoSense Pro Patch (510(k) K201234)
Review PanelClinical Chemistry
Wear Duration (cleared)14 days per patch

The Veridian Glucose Patch VGP-200 is indicated for continuous glucose monitoring in adults 18 years and older with diabetes mellitus.

Glucose readings from the VGP-200 must not be used as the sole basis for insulin dosing without confirmatory fingerstick testing during the first 48 hours of wear.

Patient health data collected by the VGP-200 is classified as PHI and must be handled per the Veridian Data Handling SOP and HIPAA Security Rule.

Mobile app companion software (VGP-App v3.1) is validated as an accessory device per 510(k) K231156-A.

Clinical Performance Data

MetricResultReference StandardAcceptance
Mean Absolute Relative Difference (MARD)8.7%YSI 2300 Stat Plus≤ 10%
Clarke Error Grid Zone A94.2%Reference glucose≥ 90%
Hypoglycemia Detection (≤70 mg/dL)Sensitivity 92.1%Reference glucose≥ 85%
Hyperglycemia Detection (≥250 mg/dL)Sensitivity 96.4%Reference glucose≥ 90%
Sensor Warm-up Time45 minutesDesign spec≤ 60 minutes

Full clinical protocol: VRD-CT-2024-001 (PDF) · Clinical Trials Registry

Data Privacy & HIPAA Requirements

Glucose data transmitted from the VGP-200 to Veridian cloud servers must be encrypted using TLS 1.3 and stored with AES-256 encryption at rest.

Patients must provide explicit HIPAA authorization before glucose data is shared with healthcare providers through the Veridian Care Portal.

Glucose trend data retained for research purposes must be de-identified per HIPAA Safe Harbor method before use.